The following article is a part of conference coverage from the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, being held virtually from February 26 to March 1, 2021. The team at Pulmonology Advisor will be reporting on the latest news and research conducted by leading experts in the field. Check back for more from the AAAAI 2021 Virtual Annual Meeting.

 

Patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) have worse health-related quality of life (HRQoL) burden than the general population despite having a history of systemic corticosteroid (SCS) and surgery, or comorbid asthma or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD), according to study findings presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting held February 26 to March 1, 2021.


Continue Reading

Previous research has shown that patients with CRSwNP, an inflammatory disease that affects the nasal cavity and paranasal sinuses, have a high burden of symptoms that significantly affect HRQoL.

This study was an analysis of baseline generic physical and mental HRQoL as well as overall health status of patients with severe CRSwNP taking background mometasone furoate in the phase 3 SINUS-24 study (ClinicalTrials.gov Identifier: NCT02912468). Baseline HRQoL was measured using the 36-Item Short-Form (SF-36) questionnaire, while overall health status was assessed using the EuroQol-5 Dimensions visual analogue scale (EQ-5D VAS). Patients were grouped by prior surgery, use of SCS within past 2 years (with or without prior surgery), and comorbid asthma or the presence of NSAID-ERD.

Overall, the mean baseline SF-36 Physical Component Score (PCS; 46.40), Mental Component Score (MCS; 48.58), and EQ-5D VAS score (66.00) in the patients with severe CRSwNP were considered below population norms (population norm levels: SF-36, 50; EQ-5D VAS, ~72). In the subgroups, the mean baseline EQ-5D VAS and SF-36 PCS scores were also considered below population norms, based on baseline asthma or NSAID-ERD or previous surgery and/or prior SCS use. The mean SF-36 MCS scores were less than 50 overall except in patients without a history of surgery (50.00) and with prior use of SCS without surgery (50.04).

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.

Reference

Maspero J, Philpott C, Hellings P, et al. Health-related quality of life impairment among patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 trial. Presented at: the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting 2021; February 26-March 1, 2021. Abstract 425.

Visit Pulmonology Advisor’s conference section for complete coverage of AAAAI 2021 Virtual Annual Meeting.